TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the “Court”) has fully dismissed the application (CV-25-00743454-00CL) (the “Application”) issued by Apollo Technology Capital Corporation (“Apollo”) and Nobul Technologies Inc. (together with Apollo, the “Applicants”) against t ...

Company Performance - atai Life Sciences N.V. has returned 81.2% year-to-date, significantly outperforming the average loss of 3.4% in the Medical sector [4] - The Zacks Consensus Estimate for atai Life Sciences N.V.'s full-year earnings has increased by 0.8% over the past three months, indicating improved analyst sentiment [4] - atai Life Sciences N.V. currently holds a Zacks Rank of 2 (Buy), suggesting a favorable earnings outlook [3] Industry Comparison - atai Life Sciences N.V. is part of the Medical - Outpatient and Home Healthcare industry, which has gained approximately 5.1% year-to-date, indicating that atai is performing better than its industry peers [6] - In contrast, Novartis, another outperforming stock in the Medical sector, has increased by 21.3% year-to-date and belongs to the Large Cap Pharmaceuticals industry, which has seen a decline of 1.1% [5][6] - The Medical sector ranks 5 in the Zacks Sector Rank, which includes 16 different groups ranked by the average Zacks Rank of individual companies [2]

Company Overview - Novo Nordisk (NVO) is headquartered in Bagsvaerd and operates in the Medical sector [3] - The stock has experienced a price decline of 16.88% since the beginning of the year [3] Dividend Information - Novo Nordisk currently pays a dividend of $0.82 per share, resulting in a dividend yield of 2.29% [3] - The company's annualized dividend of $1.64 has increased by 59.8% compared to the previous year [4] - Over the last five years, Novo Nordisk has raised its dividend five times, averaging an annual increase of 22.48% [4] - The current payout ratio is 48%, indicating that the company distributes 48% of its trailing 12-month earnings per share as dividends [4] Earnings Growth - The Zacks Consensus Estimate for Novo Nordisk's earnings in 2025 is projected at $3.84 per share, reflecting a year-over-year growth rate of 17.07% [5] Investment Considerations - Novo Nordisk is considered a strong dividend investment opportunity, especially as it is a more established company with secure profits [7] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a stable investment outlook [7]

Jilin, China, May 23, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that it has received a letter from the NASDAQ Stock Market, dated May 20, 2025 (the “Delinquency Letter”), notifying the Company that it is not in compliance with the requirements for continued list ...

Company Overview - Johnson & Johnson (JNJ) ended the latest trading session at $152.51, reflecting a -0.44% adjustment from the previous day's close, underperforming the S&P 500 which had a daily loss of 0.04% [1] - The stock has decreased by 1.42% over the past month, while the Medical sector gained 1.44% and the S&P 500 increased by 13.42% [1] Upcoming Financial Results - Analysts expect Johnson & Johnson to report earnings of $2.65 per share, indicating a year-over-year decline of 6.03% [2] - The consensus estimate for revenue is $22.77 billion, representing a 1.42% increase from the prior-year quarter [2] Annual Forecast - Zacks Consensus Estimates project earnings of $10.60 per share and revenue of $91.19 billion for the entire year, showing changes of +6.21% and +2.66% respectively compared to the previous year [3] - Recent revisions in analyst estimates are crucial as they reflect near-term business trends, with positive revisions indicating optimism about the company's profitability [3] Valuation Metrics - Johnson & Johnson is currently trading at a Forward P/E ratio of 14.45, which is a premium compared to the industry average Forward P/E of 13.21 [6] - The company has a PEG ratio of 2.32, while the Large Cap Pharmaceuticals industry has an average PEG ratio of 1.21 [6] Industry Context - The Large Cap Pharmaceuticals industry, part of the Medical sector, holds a Zacks Industry Rank of 40, placing it in the top 17% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the removal of all conditions precedent, related to its previously-announced agreement (the “Purchase Agreement”) for the sale of MediPharm’s facility in Hope, BC, (“Hope Facility”) to Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) for $4.5 million in cash (the “Transaction”). With these conditions now met, ...

Summary of Biocardia (BCDA) FY Conference Call Company Overview - Biocardia is a late-stage development company focused on autologous stem cell therapy for ischemic heart failure and chronic myocardial ischemia, located in Sunnyvale, California [1][2][5] - The company has four clinical programs at various stages of advancement [5] Core Points and Arguments Heart Failure Program - The lead indication is heart failure, specifically the BCDA DAO one cardiac phase three trial [6] - Heart failure is described as an enormous unmet medical need, with the therapy aiming to treat microvascular dysfunction by delivering high dosages of autologous cells directly into the heart muscle [6][7] - Preclinical models have shown that the therapy can reduce fibrosis and enhance capillary density [7] - The therapy includes a selection diagnostic to screen out patients who are not appropriate for treatment [7][8] Clinical Trial Data - In March, data from the heart failure one trial was presented, showing reduced mortality and improved quality of life, despite not hitting the primary endpoint [10][11] - The trial involved 115 patients and demonstrated statistical significance in secondary endpoints, including survival and reduction in major adverse cardiac events [11][12] - A one-time dosage of cells is administered, with a two-year follow-up showing robust effects [12] Upcoming Trials and Regulatory Submissions - The FDA approved a subsequent trial (Heart Failure II) to address previous enrollment challenges, with modifications to the study design [14][15] - The new trial will focus on patients with elevated markers of heart stress and aims to double the enrollment rate [19] - Biocardia is pursuing expedited approval from Japan's PMDA for cardiac cell therapy, with a submission expected within the year [21][24] - The company is also working on FDA submissions for its delivery system, which has shown excellent safety data [25] Chronic Myocardial Ischemia Program - The CardiAmp CMI program targets chronic myocardial ischemia with refractory angina, a condition poorly met by existing therapies [26][28] - There are at least one million patients in the U.S. with this condition, and Biocardia's approach aims to be the least expensive cardiac cell therapy available [30][31] - The company is working on a manuscript for early data from the low dose cohort of the CMI trial [32] Other Important Information - Biocardia has an allogeneic platform and is exploring partnerships for both cardiac and pulmonary indications [38][40] - The partnership environment is currently challenging due to market stability concerns, but Biocardia's assets are proven and in the clinic [41] - The company is focused on advancing its lead program while also exploring opportunities in other areas [39][41]

Glaukos Corporation (GKOS) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.Shares of this Zacks Rank #3 (Hold) company have lost 34.9% so far this year compared with the industry’s 7.5% decline. The S&P 500 Index has increased 0.7% in the same time frame.Glaukos, with a market capitalization of $5.48 billion, is a leading ophthalmic medical technology and pharmaceutical company. The company has a trailing four-q ...

Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement): This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as "expects", "may", "anticipates", "aims", "intends", "would", "could", "should", "will", "plans", "believes", "estimates", "targets", ...

May 12, 2025 01:56 AM GMT Eli Lilly & Co. | North America Tidbits from Zepbound vs. Wegovy SURMOUNT-5 obesity publication Investigators published SURMOUNT-5 Ph3 obesity data from a head-to-head trial of LLY's Zepbound (Tirzepatide MTD 10/15mg) vs. Novo's Wegovy (Semaglutide MTD 1.7/2.4mg) in the New England Journal of Medicine (LINK). Recall top-line data from the trial were reported in Dec 2024, see our prior note HERE. In the Zepbound group, 89.3% of the participants received at least one 15mg dose, and i ...